

ELITE PHARMACEUTICALS INC /DE/  
 Form 8-K  
 September 27, 2011

UNITED STATES  
 SECURITIES AND EXCHANGE COMMISSION  
 WASHINGTON, D.C. 20549

FORM 8-K  
 CURRENT REPORT  
 PURSUANT TO SECTION 13 OR 15(D)  
 OF THE SECURITIES EXCHANGE ACT OF 1934

September 26, 2011

\_\_\_\_\_

Date of Report (Date of earliest event reported)

ELITE PHARMACEUTICALS, INC.

(Exact name of Company as specified in its charter)

Delaware  
 (State or other jurisdiction  
 of incorporation)

001-15697  
 (Commission  
 File Number)

22-3542636  
 (IRS Employer  
 Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647

\_\_\_\_\_  
 (Address of principal executive offices)

(201) 750-2646

\_\_\_\_\_  
 (Company's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events

On September 27, 2011, Elite Pharmaceuticals, Inc. (the "Company") issued a press release to announce with ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal, the launch of Lodrane D®. Lodrane D® is an immediate release formulation of brompheniramine maleate and pseudoephedrine HCl. Elite will manufacture the product for ECR and will receive revenues for the manufacturing, packaging, and laboratory stability study services for this product, as well as royalties on sales.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

- a) Not applicable.
- b) Not applicable.
- c) Not applicable.
- d) Exhibits

Exhibit No. Exhibit

99.1 Press Release dated September 27, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 27, 2011

ELITE PHARMACEUTICALS, INC.

By: /s/ Chris Dick  
Name: Chris Dick  
Title: President & Chief Operating Officer